HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

XUANZHUBIO-B

8.940

+0.0600.68%

Volume:1.97M

Turnover:17.01M

Market Cap:4.63B

PE:-14.43

High:8.940

Open:8.875

Low:8.005

Close:8.880

52wk High:96.900

52wk Low:8.005

Shares:518.00M

HK Float Shares:517.95M

Volume Ratio:0.85

T/O Rate:0.38%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.619

ROE:-19.61%

ROA:-9.68%

PB:3.06

PE(LYR):-14.43

PS:38.35

Loading ...

Overview Company News Filings

Xuanzhu Biopharmaceutical Co Ltd - Approved to Initiate Phase Iii Trial of Anaprazole Sodium for Helicobacter Pylori Eradication

THOMSON REUTERS

Stock Track | XUANZHUBIO-B Soars 12.58% in Afternoon Trading on H-Share Reform Approval and Lucrative Drug Licensing Deal

XUANZHUBIO-B Shares Surge Over 12% in Afternoon Trading Following H-Share Reform Approval and Drug Licensing Deals

Xuanzhu Biopharmaceutical secures CSRC approval to convert 357.25 million domestic shares into H-shares

Bulletin Express

XuanZhu Bio-B Receives Regulatory Approval for H-Share Full Circulation Plan

BUZZ-China's Xuanzhu set for best day in 6 months on drug deal with Boston Oncology

Xuanzhu Biotech-B Surges Over 10% in Morning Session Following Licensing Pact with Boston Oncology

BRIEF-Xuanzhu Biopharmaceutical Enters Licensing Agreement With Boston Oncology

XuanZhuBio-B Forges Licensing and Supply Pact for Cancer Drugs with Boston Oncology

Xuanzhu Biopharm licenses breast cancer, lung cancer drugs to Boston Oncology in MENA deal

Xuanzhu Biopharmaceutical - Group to Receive Payments Exceeding $100 Mln and Royalties Under Agreement

THOMSON REUTERS

Xuanzhu Biopharmaceutical - Xuanzhubio-B Enters Licensing Agreement With Boston Oncology for Bireociclib and Dirozalkib on April 9, 2026

THOMSON REUTERS

Stock Track | XUANZHUBIO-B Soars 12.96% in Morning Session on Strong FY2025 Earnings

XUANZHUBIO-B Shares Surge Over 12% in Morning Session on Strong FY2025 Earnings

XuanZhu Bio-B Reports Annual Revenue Surge of 72.03% to 51.772 Million Yuan

Xuanzhu Biopharma FY25 loss narrows 55.9% to RMB 250 million

XuanZhuBio-B Shares Surge Over 18% Following Publication of Bireociclib Phase III Trial Results in Top Medical Journal

HK Pharma Stocks Gained. XuanzhuBio Up 9%; Xtalpi, Lepu Bio And Ascletis Up 6%; Akeso Up 5%; Skb Bio Up 4%.

Tiger Newspress

XUANZHUBIO-B (02575) Final Analysis of Phase III Trial for Bireociclib Plus Fulvestrant in HR+/HER2- Advanced Breast Cancer Published in Top-Tier Journal JAMA Oncology

Xuanzhu Biopharmaceutical reports BRIGHT-2 Phase 3 results for Bireociclib plus fulvestrant in HR+/HER2- breast cancer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/02575/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02575","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","market":"HK","secType":"STK","nameCN":"XUANZHUBIO-B","latestPrice":8.94,"timestamp":1789114135003,"preClose":8.88,"halted":0,"volume":1972000,"delay":0,"changeRate":0.006756756756756612,"floatShares":517947790,"shares":518000000,"eps":-0.619450670096221,"marketStatus":"Closed","change":0.06,"latestTime":"09-11 16:08:55","open":8.875,"high":8.94,"low":8.005,"amount":17013725,"amplitude":0.105293,"askPrice":8.94,"askSize":6000,"bidPrice":8.605,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.49223537163089426,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":5,"adr":0,"listingDate":1760457600000,"exchange":"SEHK","adjPreClose":8.88,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"volumeRatio":0.850691,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","floatShares":517947790,"roa":"-9.68%","roe":"-19.61%","lyrEps":-0.619451,"volumeRatio":0.850691,"shares":518000000,"dividePrice":0,"high":8.94,"amplitude":0.105293,"preClose":8.88,"low":8.005,"week52Low":8.005,"pbRate":"3.06","psRate":"38.35","week52High":96.9,"institutionHeld":0,"latestPrice":8.94,"committee":-0.846154,"eps":-0.619450670096221,"divideRate":0,"volume":1972000,"delay":0,"ttmEps":-0.49223537163089426,"open":8.875,"prevYearClose":70.5,"prevWeekClose":10.43,"prevMonthClose":10.08,"prevQuarterClose":13.33,"fiveDayClose":10.43,"twentyDayClose":12.36,"sixtyDayClose":16.27},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02575\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"02575","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null},{"date":"2026-03-30","symbol":"02575","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02575\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02575\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02575\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02575","date":"2026-09-10","current":-18.162043,"percent":0.995475,"low":-70.039607,"twenty":-55.043957,"median":-41.917472,"eighty":-24.026085,"high":-18.714723,"avg":-40.945326,"sd":14.545267,"marketCap":4599376375},"quantilePoints":[{"date":"2025-10-17","current":-28.93414,"twenty":-27.261252,"median":-24.751919,"eighty":-23.367582,"marketCap":17558430081},{"date":"2025-10-24","current":-50.850969,"twenty":-50.816841,"median":-33.923646,"eighty":-26.424807,"marketCap":30869688284},{"date":"2025-10-31","current":-54.182971,"twenty":-53.663557,"median":-50.808309,"eighty":-28.95487,"marketCap":32941479444},{"date":"2025-11-07","current":-55.367666,"twenty":-55.639174,"median":-53.630543,"eighty":-30.992132,"marketCap":33640708960},{"date":"2025-11-14","current":-54.36116,"twenty":-55.639174,"median":-54.1994,"eighty":-41.200731,"marketCap":33122761170},{"date":"2025-11-21","current":-53.748657,"twenty":-55.319259,"median":-54.136108,"eighty":-50.782713,"marketCap":32734300328},{"date":"2025-11-28","current":-53.384655,"twenty":-55.070724,"median":-54.15954,"eighty":-50.923112,"marketCap":32630710770},{"date":"2025-12-05","current":-54.773392,"twenty":-55.070724,"median":-54.21583,"eighty":-51.627953,"marketCap":33537119402},{"date":"2025-12-12","current":-70.039607,"twenty":-55.665823,"median":-54.261136,"eighty":-53.311356,"marketCap":42963769180},{"date":"2025-12-19","current":-60.019152,"twenty":-56.570931,"median":-54.488669,"eighty":-53.433833,"marketCap":36903780037},{"date":"2025-12-24","current":-59.160975,"twenty":-59.157371,"median":-54.549256,"eighty":-53.581365,"marketCap":36489421805},{"date":"2026-01-02","current":-54.537602,"twenty":-59.158272,"median":-54.690337,"eighty":-53.655303,"marketCap":33770195908},{"date":"2026-01-09","current":-52.983682,"twenty":-59.049917,"median":-54.49123,"eighty":-52.274882,"marketCap":32889684665},{"date":"2026-01-16","current":-58.758617,"twenty":-58.846722,"median":-54.572443,"eighty":-53.169291,"marketCap":36593011363},{"date":"2026-01-23","current":-52.071916,"twenty":-58.705513,"median":-54.4959,"eighty":-52.506318,"marketCap":32397634264},{"date":"2026-01-30","current":-53.326607,"twenty":-57.909955,"median":-54.48995,"eighty":-52.506318,"marketCap":33329940286},{"date":"2026-02-06","current":-57.283358,"twenty":-57.848985,"median":-54.4959,"eighty":-52.506318,"marketCap":35893781847},{"date":"2026-02-13","current":-51.942748,"twenty":-58.578655,"median":-54.516751,"eighty":-52.506318,"marketCap":32734300328},{"date":"2026-02-20","current":-51.153455,"twenty":-58.517685,"median":-54.493565,"eighty":-52.321662,"marketCap":32190455148},{"date":"2026-02-27","current":-53.732962,"twenty":-57.403185,"median":-54.403912,"eighty":-52.138331,"marketCap":34184554140},{"date":"2026-03-06","current":-41.037619,"twenty":-57.295346,"median":-54.261136,"eighty":-51.687579,"marketCap":25897389500},{"date":"2026-03-13","current":-40.849477,"twenty":-57.283358,"median":-54.21583,"eighty":-50.904735,"marketCap":25897389500},{"date":"2026-03-20","current":-35.26408,"twenty":-56.603099,"median":-54.112473,"eighty":-49.228933,"marketCap":22271754970},{"date":"2026-03-27","current":-28.858752,"twenty":-56.47148,"median":-53.935449,"eighty":-43.741043,"marketCap":18179967429},{"date":"2026-04-02","current":-57.594339,"twenty":-56.497804,"median":-53.833069,"eighty":-43.169536,"marketCap":16087458357},{"date":"2026-04-10","current":-59.545661,"twenty":-57.25627,"median":-53.970491,"eighty":-43.400861,"marketCap":16760790484},{"date":"2026-04-17","current":-61.727863,"twenty":-57.517877,"median":-54.136108,"eighty":-43.645588,"marketCap":17382327832},{"date":"2026-04-24","current":-45.649544,"twenty":-57.360049,"median":-54.047185,"eighty":-44.053945,"marketCap":12855464147},{"date":"2026-04-30","current":-39.643505,"twenty":-57.292948,"median":-53.884259,"eighty":-43.829171,"marketCap":11166954352},{"date":"2026-05-08","current":-39.029961,"twenty":-57.269814,"median":-53.732962,"eighty":-42.509315,"marketCap":11032287927},{"date":"2026-05-15","current":-34.724128,"twenty":-57.211578,"median":-53.651177,"eighty":-40.906347,"marketCap":9841008010},{"date":"2026-05-22","current":-32.788719,"twenty":-57.162996,"median":-53.511235,"eighty":-40.250137,"marketCap":9271265441},{"date":"2026-05-29","current":-29.882198,"twenty":-57.033621,"median":-53.326607,"eighty":-39.029961,"marketCap":8478805322},{"date":"2026-06-05","current":-31.916861,"twenty":-56.603099,"median":-53.185623,"eighty":-36.605471,"marketCap":9069265802},{"date":"2026-06-12","current":-29.603728,"twenty":-56.47148,"median":-52.629422,"eighty":-35.26408,"marketCap":8406292631},{"date":"2026-06-18","current":-30.479088,"twenty":-56.448102,"median":-52.321662,"eighty":-34.687576,"marketCap":8675625482},{"date":"2026-06-26","current":-23.369212,"twenty":-56.068362,"median":-52.035899,"eighty":-32.252252,"marketCap":6619372756},{"date":"2026-07-03","current":-26.037742,"twenty":-55.925853,"median":-51.815163,"eighty":-31.259875,"marketCap":7380756007},{"date":"2026-07-10","current":-23.563382,"twenty":-55.788956,"median":-51.211683,"eighty":-30.461424,"marketCap":6671167535},{"date":"2026-07-17","current":-22.969392,"twenty":-55.712025,"median":-50.877852,"eighty":-29.911789,"marketCap":6526142154},{"date":"2026-07-24","current":-21.396832,"twenty":-55.583366,"median":-50.208288,"eighty":-29.704477,"marketCap":6080707054},{"date":"2026-07-31","current":-19.991935,"twenty":-55.489987,"median":-48.334812,"eighty":-29.33959,"marketCap":5692246212},{"date":"2026-08-07","current":-22.658402,"twenty":-55.433258,"median":-45.681548,"eighty":-28.96324,"marketCap":6463988419},{"date":"2026-08-14","current":-22.412159,"twenty":-55.37071,"median":-44.835824,"eighty":-28.336789,"marketCap":6401834684},{"date":"2026-08-21","current":-20.01067,"twenty":-55.365612,"median":-44.352491,"eighty":-26.122142,"marketCap":5728502557},{"date":"2026-08-28","current":-22.359148,"twenty":-55.267771,"median":-43.581952,"eighty":-25.329792,"marketCap":5474708140},{"date":"2026-09-04","current":-22.054147,"twenty":-55.10047,"median":-42.591003,"eighty":-24.406781,"marketCap":5402195449},{"date":"2026-09-10","current":-18.751381,"twenty":-55.043957,"median":-41.917472,"eighty":-24.026085,"marketCap":4599376375}],"updateTime":1789116469331},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02575\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2627545427","title":"Xuanzhu Biopharmaceutical Co Ltd - Approved to Initiate Phase Iii Trial of Anaprazole Sodium for Helicobacter Pylori Eradication","url":"https://stock-news.laohu8.com/highlight/detail?id=2627545427","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627545427?lang=en_us&edition=fundamental","pubTime":"2026-04-15 06:06","pubTimestamp":1776204413,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nFWN40X16Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132796697","title":"Stock Track | XUANZHUBIO-B Soars 12.58% in Afternoon Trading on H-Share Reform Approval and Lucrative Drug Licensing Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1132796697","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132796697?lang=en_us&edition=fundamental","pubTime":"2026-04-14 14:12","pubTimestamp":1776147162,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B's stock surged 12.58% during afternoon trading on Tuesday, marking a significant upward movement for the biopharmaceutical company.The sharp rise follows the company's announcement that...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142636519","title":"XUANZHUBIO-B Shares Surge Over 12% in Afternoon Trading Following H-Share Reform Approval and Drug Licensing Deals","url":"https://stock-news.laohu8.com/highlight/detail?id=1142636519","media":"Stock News","labels":["corporation","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142636519?lang=en_us&edition=fundamental","pubTime":"2026-04-14 14:10","pubTimestamp":1776147021,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) saw its shares rise more than 12% in afternoon trading. At the time of writing, the stock was up 4.97%, trading at HK$32.54 with a turnover of HK$80.7147 million. The company...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","BK1191","BK4585","BK4588","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127927706","title":"Xuanzhu Biopharmaceutical secures CSRC approval to convert 357.25 million domestic shares into H-shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1127927706","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127927706?lang=en_us&edition=fundamental","pubTime":"2026-04-12 18:21","pubTimestamp":1775989280,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. announced that it has received an official notification from the China Securities Regulatory Commission (CSRC) confirming completion of its filing for an H-share...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165876354","title":"XuanZhu Bio-B Receives Regulatory Approval for H-Share Full Circulation Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1165876354","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165876354?lang=en_us&edition=fundamental","pubTime":"2026-04-12 18:06","pubTimestamp":1775988373,"startTime":"0","endTime":"0","summary":"XuanZhu Bio-B (02575) has announced that it recently received a formal filing notice from the China Securities Regulatory Commission regarding its application for an H-share full circulation plan....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626116838","title":"BUZZ-China's Xuanzhu set for best day in 6 months on drug deal with Boston Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2626116838","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626116838?lang=en_us&edition=fundamental","pubTime":"2026-04-10 11:06","pubTimestamp":1775790406,"startTime":"0","endTime":"0","summary":"BUZZ-China's Xuanzhu set for best day in 6 months on drug deal with Boston Oncology** Shares of drugmaker Xuanzhu Biopharmaceutical 2575.HK jump 18.1% to HK$37** Set for the biggest one-day pct rise since Oct 22** Stock also hit highest level since March 27 in the fifth session of gain** Cambridge, Massachusetts-based oncology drugmaker Boston Oncology CGT Holding will license Xuanzhu's breast cancer treatment Bireociclib and lung cancer treatment Dirozalkib** Payments to exceed $100 million if milestones are met ** Under agreement, Sihuan Pharmaceutical 0460.HK unit Xuanzhu is eligible to receive an upfront payment, regulatory and sales-related milestone payments, royalties based on sales** YTD, Xuanzhu stock down 50.6%, while Sihuan Pharmaceutical shares up 15.5%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nL1N40T02K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1600","00460","BK1191","BK1515","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117603074","title":"Xuanzhu Biotech-B Surges Over 10% in Morning Session Following Licensing Pact with Boston Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=1117603074","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117603074?lang=en_us&edition=fundamental","pubTime":"2026-04-10 09:38","pubTimestamp":1775785106,"startTime":"0","endTime":"0","summary":"Xuanzhu Biotech-B (02575) saw its shares rise more than 10% during the morning trading session. At the time of writing, the stock was up 9.96%, trading at HK$34.46 with a turnover of HK$3.4138...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK1191","BK4588","02575","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626990782","title":"BRIEF-Xuanzhu Biopharmaceutical Enters Licensing Agreement With Boston Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2626990782","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626990782?lang=en_us&edition=fundamental","pubTime":"2026-04-09 16:44","pubTimestamp":1775724248,"startTime":"0","endTime":"0","summary":"BRIEF-Xuanzhu Biopharmaceutical Enters Licensing Agreement With Boston OncologyApril 9  - Xuanzhu Biopharmaceutical Co Ltd 2575.HK:XUANZHUBIO-B ENTERS LICENSING AGREEMENT WITH BOSTON ONCOLOGY FOR BIREOCICLIB AND DIROZALKIB ON APRIL 9, 2026BOSTON ONCOLOGY GRANTED EXCLUSIVE LICENSE FOR BIREOCICLIB AND DIROZALKIB IN 21 MENA COUNTRIESGROUP TO RECEIVE PAYMENTS EXCEEDING $100 MILLION AND ROYALTIES UNDER AGREEMENTFurther company coverage: 2575.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nFWN40S0JV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1515","BK1600","BK1191","02575","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158022839","title":"XuanZhuBio-B Forges Licensing and Supply Pact for Cancer Drugs with Boston Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=1158022839","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158022839?lang=en_us&edition=fundamental","pubTime":"2026-04-09 16:38","pubTimestamp":1775723905,"startTime":"0","endTime":"0","summary":"XuanZhuBio-B (02575) announced that on April 9, 2026, the Group, as the licensor, entered into a licensing and supply agreement with Boston Oncology CGT Holding Co. Limited, the licensee, concerning...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626211902","title":"Xuanzhu Biopharm licenses breast cancer, lung cancer drugs to Boston Oncology in MENA deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2626211902","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626211902?lang=en_us&edition=fundamental","pubTime":"2026-04-09 16:34","pubTimestamp":1775723686,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharm signed licensing and supply agreement with Boston Oncology CGT on April 9, 2026, covering cancer drugs bireociclib and dirozalkib.Deal grants Boston Oncology exclusive rights to develop, register, commercialize both drugs across 21 Middle East and North Africa markets.Xuanzhu Biopharm expects upfront payment, regulatory and commercial milestones that may exceed USD 100 million.Agreement also includes royalties at fixed percentage of sales in licensed territory.Xuanzhu Biopharm will supply products to Boston Oncology at agreed supply prices to support commercialization in region.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news br","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL4tmr89:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1191","BK1515","BK1600","02575","00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626902213","title":"Xuanzhu Biopharmaceutical - Group to Receive Payments Exceeding $100 Mln and Royalties Under Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2626902213","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626902213?lang=en_us&edition=fundamental","pubTime":"2026-04-09 16:33","pubTimestamp":1775723618,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nFWN40S0JV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626024259","title":"Xuanzhu Biopharmaceutical - Xuanzhubio-B Enters Licensing Agreement With Boston Oncology for Bireociclib and Dirozalkib on April 9, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2626024259","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626024259?lang=en_us&edition=fundamental","pubTime":"2026-04-09 16:33","pubTimestamp":1775723618,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nFWN40S0JV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160268323","title":"Stock Track | XUANZHUBIO-B Soars 12.96% in Morning Session on Strong FY2025 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=1160268323","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160268323?lang=en_us&edition=fundamental","pubTime":"2026-04-02 09:53","pubTimestamp":1775094813,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B's stock price soared 12.96% during the morning trading session, following the release of the company's annual financial results for the fiscal year ending December 31, 2025.The surge is...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121401258","title":"XUANZHUBIO-B Shares Surge Over 12% in Morning Session on Strong FY2025 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=1121401258","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121401258?lang=en_us&edition=fundamental","pubTime":"2026-04-02 09:50","pubTimestamp":1775094646,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) saw its shares rise more than 12% during the morning trading session. As of the time of writing, the stock was up 12.24%, trading at HK$34, with a turnover of HK$6.5058 million....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","02575","BK4585","BK1191","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114719347","title":"XuanZhu Bio-B Reports Annual Revenue Surge of 72.03% to 51.772 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1114719347","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114719347?lang=en_us&edition=fundamental","pubTime":"2026-03-30 18:06","pubTimestamp":1774865209,"startTime":"0","endTime":"0","summary":"XuanZhu Bio-B (02575) announced its financial results for the year ended December 31, 2025. The group recorded revenue of 51.772 million yuan, representing a year-on-year increase of 72.03%. Gross...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623315221","title":"Xuanzhu Biopharma FY25 loss narrows 55.9% to RMB 250 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623315221","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623315221?lang=en_us&edition=fundamental","pubTime":"2026-03-30 17:58","pubTimestamp":1774864687,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical posted a net loss of RMB 250 million, narrowing 55.9%.Operating expenses fell 56.6% to RMB 250 million.Commercial rollout accelerated with two oncology launches in 2025, while cash and cash equivalents climbed to RMB 650 million following the October IPO.For 2026, focus remains on expanding NRDL access, advancing indication expansions and pipeline development, while tightening cost management.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL414TVf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575","00460","BK1515","BK1600","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187286061","title":"XuanZhuBio-B Shares Surge Over 18% Following Publication of Bireociclib Phase III Trial Results in Top Medical Journal","url":"https://stock-news.laohu8.com/highlight/detail?id=1187286061","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187286061?lang=en_us&edition=fundamental","pubTime":"2026-03-26 09:54","pubTimestamp":1774490060,"startTime":"0","endTime":"0","summary":"XuanZhuBio-B (02575) rose more than 18% during morning trading. At the time of writing, the stock was up 11.85% to HK$40.58, with a turnover of HK$18.864 million. The surge follows an announcement on...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0146","BK0046","BK1191","BK0114","BK4588","BK0042","BK0077","BK0181","VXUS","BK4134","III","02575","BK4585","000516","BK0096","BK0188","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148472362","title":"HK Pharma Stocks Gained. XuanzhuBio Up 9%; Xtalpi, Lepu Bio And Ascletis Up 6%; Akeso Up 5%; Skb Bio Up 4%.","url":"https://stock-news.laohu8.com/highlight/detail?id=1148472362","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148472362?lang=en_us&edition=fundamental","pubTime":"2026-03-26 09:54","pubTimestamp":1774490045,"startTime":"0","endTime":"0","summary":"HK Pharma Stocks Gained. XuanzhuBio up 9%; Xtalpi, Lepu Bio and Ascletis up 6%; Akeso up 5%; Skb Bio up 4%. ","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06606","02269","02228","02359","03759","02575","09688","09995","02268","03347","02157","06978","09966","02137","09606","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198477232","title":"XUANZHUBIO-B (02575) Final Analysis of Phase III Trial for Bireociclib Plus Fulvestrant in HR+/HER2- Advanced Breast Cancer Published in Top-Tier Journal JAMA Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=1198477232","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198477232?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:16","pubTimestamp":1774351001,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) announced that the final analysis results of the Phase III BRIGHT-2 clinical study for its self-developed novel CDK2/4/6 inhibitor, Bireociclib, have been formally published...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HR","BK4134","BK4203","BK4225","02575","III","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621069888","title":"Xuanzhu Biopharmaceutical reports BRIGHT-2 Phase 3 results for Bireociclib plus fulvestrant in HR+/HER2- breast cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2621069888","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621069888?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:06","pubTimestamp":1774350387,"startTime":"0","endTime":"0","summary":"Xuanzhu reported final Phase 3 BRIGHT-2 results for its breast cancer product bireociclib in combination with fulvestrant, with the analysis published in JAMA Oncology.The company said median progression-free survival was 14.7 months versus 7.3 months for placebo plus fulvestrant, with a 46% reduction in risk of progression or death .In patients with measurable disease, the objective response rate was 50.3% versus 16.7% for the control group.Xuanzhu said bireociclib has been approved in China for use with fulvestrant in HR+/HER2- advanced or metastatic breast cancer after progression on prior endocrine therapy, positioning it for broader clinical adoption.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL20tgp6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","02575","BK1191","BK1593","00460","BK1515"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":85,"code":"91000000","status":"200"}]}}